## Marcus Ulrich Hentrich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/297691/publications.pdf

Version: 2024-02-01

68 papers 2,216 citations

236925 25 h-index 243625 44 g-index

74 all docs

74 docs citations

74 times ranked 2793 citing authors

#	Article	IF	CITATIONS
1	Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study. Cancer, 2022, 128, 260-268.	4.1	1
2	Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210868.	3.2	4
3	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology. 2021. 100. 321-336.	1.8	34
4	Improved outcomes in metastatic germ cell cancer: results from a large cohort study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 533-538.	2.5	8
5	Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study. Acta Oncol $ ilde{A}^3$ gica, 2021, 60, 24-27.	1.8	11
6	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). World Journal of Urology, 2021, 39, 3407-3414.	2.2	4
7	Characteristics and outcome of human immunodeficiency virus (HIV)â€associated primary effusion lymphoma as observed in the German HIVâ€related lymphoma cohort study. British Journal of Haematology, 2021, 194, 642-646.	2.5	12
8	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. Journal of Clinical Oncology, 2021, 39, 1553-1562.	1.6	83
9	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of Clinical Oncology, 2021, 39, 1563-1574.	1.6	108
10	Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respiratory Medicine, the, 2021, 9, 863-872.	10.7	75
11	Central venous catheter–related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology, 2021, 100, 239-259.	1.8	54
12	Overweight or obesity are not risk factors for central venous catheter–related bloodstream infections in patients with hematological malignancies. Infection Control and Hospital Epidemiology, 2021, , 1-3.	1.8	1
13	Central venous catheter–related bloodstream infections in patients with hematological malignancies: Comparison of data from a clinical registry and a randomized controlled trial. Infection Control and Hospital Epidemiology, 2020, 41, 1-3.	1.8	9
14	Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. Journal of Cancer Research and Clinical Oncology, 2020, 146, 449-455.	2.5	10
15	Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. Journal of Clinical Oncology, 2020, 38, 1322-1331.	1.6	23
16	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). European Journal of Cancer, 2020, 140, 86-104.	2.8	33
17	Treatment of invasive fungal diseases in cancer patientsâ€"Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses, 2020, 63, 653-682.	4.0	42
18	Outcome of men with HIV-associated germ cell cancer: Results from an international collaborative study Journal of Clinical Oncology, 2020, 38, 5053-5053.	1.6	O

#	Article	IF	CITATIONS
19	Impact of neutropenia on central venous catheter–related bloodstream infections in patients with hematological malignancies at the time of central venous catheter insertion: A matched-pair analysis. Infection Control and Hospital Epidemiology, 2019, 40, 1204-1206.	1.8	7
20	The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). Urologic Oncology: Seminars and Original Investigations, 2019, 37, 809.e19-809.e25.	1.6	10
21	Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia, 2019, 33, 2710-2719.	7.2	28
22	Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. Journal of Clinical Oncology, 2019, 37, 1412-1423.	1.6	246
23	Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. Bone Marrow Transplantation, 2019, 54, 1625-1631.	2.4	11
24	Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis. Blood Advances, 2019, 3, 2696-2699.	5.2	8
25	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. Journal of Cancer Research and Clinical Oncology, 2019, 145, 717-723.	2.5	25
26	Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma Journal of Clinical Oncology, 2019, 37, 510-510.	1.6	1
27	Malignant lymphoma in the <scp>HIV</scp> â€positive patient. European Journal of Haematology, 2018, 101, 119-126.	2.2	25
28	Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica, 2018, 103, 857-864.	3 <b>.</b> 5	27
29	Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors. European Journal of Cancer, 2018, 94, 16-25.	2.8	10
30	HIV-Associated Lung Cancer. Oncology Research and Treatment, 2017, 40, 88-92.	1.2	16
31	HIV-Associated Urogenital Malignancies. Oncology Research and Treatment, 2017, 40, 106-112.	1.2	10
32	HIV-Associated Malignant Lymphoma. Oncology Research and Treatment, 2017, 40, 82-87.	1.2	27
33	Nivolumab in HIV-related non-small-cell lung cancer. Annals of Oncology, 2017, 28, 2890.	1.2	27
34	FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry Journal of Clinical Oncology, 2017, 35, 4521-4521.	1.6	11
35	Intermediate prognosis in metastatic germ cell tumors (IPGCT): Outcome and prognostic factors Journal of Clinical Oncology, 2017, 35, 4560-4560.	1.6	О
36	CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. Aids, 2016, 30, 753-760.	2.2	13

#	Article	IF	CITATIONS
37	Severe motor aphasia after reinfusion of cryopreserved autologous stem cells after myeloablative conditioning. Transfusion, 2016, 56, 2615-2617.	1.6	4
38	Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica, 2016, 101, 1398-1406.	3.5	28
39	Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party. Blood, 2016, 128, 2257-2257.	1.4	3
40	Antiviral prophylaxis in patients with solid tumours and haematological malignanciesâ€"update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Annals of Hematology, 2015, 94, 1441-1450.	1.8	98
41	Survival of <scp>AIDS</scp> â€related diffuse large Bâ€cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German <scp>HIV</scp> Lymphoma Cohort. British Journal of Haematology, 2015, 168, 806-810.	2.5	53
42	Efficacy and safety of gemcitabine, oxaliplatin and paclitaxel (GOP) in cisplatin-refractory germ cell tumors in routine care: Registry data from an outcomes research project Journal of Clinical Oncology, 2015, 33, e15570-e15570.	1.6	O
43	Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. Leukemia and Lymphoma, 2014, 55, 2341-2348.	1.3	34
44	Should the standard dimethyl sulfoxide concentration be reduced? Results of a <scp>E</scp> uropean <scp>G</scp> roup for <scp>B</scp> lood and <scp>M</scp> arrow <scp>T</scp> ransplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. Transfusion, 2014, 54, 2514-2522.	1.6	75
45	Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Annals of Hematology, 2014, 93, 1083-1095.	1.8	86
46	First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). Journal of Cancer Research and Clinical Oncology, 2014, 140, 1211-20.	2.5	11
47	Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÃ,,), in cooperation with the German AIDS Society (DAIG). Annals of Hematology, 2014, 93, 913-921.	1.8	33
48	Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma. Blood, 2014, 124, 3969-3969.	1.4	1
49	Poor outcome of HIV-infected patients with plasmablastic lymphoma. Aids, 2013, 27, 842-845.	2.2	57
50	Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica, 2013, 98, 1762-1768.	3.5	27
51	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 1062-1067.	1.3	23
52	Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study. Journal of Clinical Oncology, 2012, 30, 4117-4123.	1.6	111
53	Treatment of AIDS-related lymphomas. Aids, 2012, 26, 457-464.	2.2	29
54	Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients. Blood, 2012, 120, 2012-2012.	1.4	4

#	Article	IF	CITATIONS
55	Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. Blood, 2011, 117, 2121-2128.	1.4	15
56	Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood, 2009, 113, 3903-3910.	1.4	57
57	Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer. Acta Oncológica, 2008, 47, 155-156.	1.8	16
58	Tissue Levels of Reduced Folates in Patients with Colorectal Carcinoma After Infusion of Folinic Acid at Various Dose Levels. Clinical Cancer Research, 2008, 14, 7930-7934.	7.0	8
59	AIDS-associated Burkitt or Burkitt-like lymphoma: Short intensive polychemotherapy is feasible and effective. Leukemia and Lymphoma, 2006, 47, 1872-1880.	1.3	25
60	IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial*. Critical Care Medicine, 2006, 34, 1319-1325.	0.9	77
61	Smoking cessation in long-term survivors of germ cell tumour. Journal of Cancer Research and Clinical Oncology, 2006, 132, 557-560.	2.5	15
62	Acquired immunodeficiency syndrome-related lymphoma. Cancer, 2006, 106, 1560-1568.	4.1	77
63	Autologous Stem Cell Transplantation (ASCT) in HIV Associated Lymphoma (HIV-Ly) Patients: The EBMT Lymphoma Working Party (EBMT-LWP) Experience Blood, 2006, 108, 3042-3042.	1.4	3
64	Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. British Journal of Haematology, 2005, 128, 66-72.	2.5	144
65	Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich. Acta Oncol $\tilde{A}^3$ gica, 2005, 44, 529-536.	1.8	47
66	Bortezomib in Combination with High-Dose Dexamethasone and Continuous Low-Dose Oral Cyclophosphamide for Relapsed Multiple Myeloma Blood, 2005, 106, 2549-2549.	1.4	19
67	Early Autologous Stem Cell Transplantation (SCT) in Genetically Poor-Risk Chronic Lymphocytic Leukemia Is Feasible and Effective: Results from a Prospective Multicenter Study (GCLLSG CLL3) Tj ETQq1 1 0.75	84311 <b>4</b> rgB	T / <b>@</b> verlock <u>1</u>
68	Etoposide, Cisplatin, Bleomycin, And Cyclophosphamide (Ecbc) As First-Line Chemotherapy for Poor-Risk Non-Seminomatous Germ Cell Tumors. Acta Oncol $ ilde{A}^3$ gica, 1993, 32, 541-546.	1.8	13